georgia
TRANSCRIPT
Overview of HIV/AIDS in GeorgiaOverview of HIV/AIDS in Georgia
Ketevan Mshvidobadze, MD, PhDKetevan Mshvidobadze, MD, PhD
Overview of HIV/AIDS in GeorgiaOverview of HIV/AIDS in Georgia
Ketevan Mshvidobadze, MD, PhDKetevan Mshvidobadze, MD, PhD
Women 524
Men 1526
05
1015
2025
3035
40
Distribution of HIV/AIDS Patients by Sex and Age GroupsDistribution of HIV/AIDS Patients by Sex and Age Groups
Age distribution
Infectious Diseases, AIDS Infectious Diseases, AIDS & Clinical Immunology& Clinical Immunology
Research CenterResearch Center
AIDS - 1044 Deaths - 440
HIV Cases Registered in Georgia AnnuallyHIV Cases Registered in Georgia AnnuallyN
um
be
r o
f ca
ses
Nu
mb
er
of
cas
es
Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center
1 3 1 6 0 6 2 8 2125 34
79 9395100
163
242276
344351
201
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
1 3 1 6 0 6 2 8 2125 34
79 9395100
163
242276
344351
201
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Undetermined
1.4%
Mother to child transmission
2.3%
Homo/Bi-sexual contacts
2.7%
Blood transfusion
0.6%
Heterosexual contacts
33.4%
Injecting drug use
59.7%
Distribution of HIV Cases by Routes Distribution of HIV Cases by Routes
of Transmissionof Transmission
Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center
Universal Access Universal Access to HIV Treatment, Care and Support to HIV Treatment, Care and Support
and Preventionand Prevention
Georgia Is the First Among FSU Countries that from 2004
Ensured Universal (100%) Access to ARV Treatment.
Georgia Is the First Among FSU Countries that from 2004
Ensured Universal (100%) Access to ARV Treatment.
Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center
RUSRUS**
ARM*ARM*
KAZ*KAZ*
KGZ*KGZ*UZB*UZB*
TKMTKMTJK*TJK*
AZE*AZE*
BEL*BEL*
UKRUKR**
no HAART individuals on HAART (<1%) * in the process of scaling up ART
very poor access ( 1-25%) poor access (25-50%) disputed coverage estimates or
insufficient data available
moderate access (50-75%) good access (over 75%)
ALB* FYM*
GEOGEO
Access to HAART, 2008
National AIDS National AIDS
CenterCenter
Three Regional Three Regional
AIDS Treatment AIDS Treatment
CentersCenters
National AIDS National AIDS
CenterCenter
Three Regional Three Regional
AIDS Treatment AIDS Treatment
CentersCenters
TbilisiBatumi
Zugdidi
Kutaisi
Infectious Diseases, AIDS & Clinical Immunology Research CenterInfectious Diseases, AIDS & Clinical Immunology Research Center
Decentralisation of HIV Treatment Decentralisation of HIV Treatment and Care Process in Georgiaand Care Process in Georgia
Decentralisation of HIV Treatment Decentralisation of HIV Treatment and Care Process in Georgiaand Care Process in Georgia
ARV TreatmentARV Treatment
547 Patients are currently receiving ART
547 Patients are currently receiving ART
521 521 adultsadults521 521
adultsadults
26 26 childrenchildren
26 26 childrenchildren
Infectious Diseases, AIDS & Clinical Immunology Research Center
Salvage Regimens – WHO(Regimens for highly treatment experienced patients)
• Currently available: Enfurvitide (Fusion inhibitor) Darunavir (PI)
• Starting 2010 through extended Global Fund project: Raltegravir (Integrase inhibitor) Etravirine (NNRTI) Tipranavir (PI) Maraviroc (Entry inhibitor)
• Currently available: Enfurvitide (Fusion inhibitor) Darunavir (PI)
• Starting 2010 through extended Global Fund project: Raltegravir (Integrase inhibitor) Etravirine (NNRTI) Tipranavir (PI) Maraviroc (Entry inhibitor)
Infectious Diseases, AIDS & Clinical Immunology Research Center
Thank you